Distinguishing between pseudoseizures and true seizures can be challenging as they share some similarities. However, one key difference is that pseudoseizures tend to have a gradual onset, while true seizures have a sudden onset. Pseudoseizures are often linked to psychiatric conditions and are not voluntary, but rather compulsive and unwanted movements. It is common for individuals experiencing pseudoseizures to have some control over the location of their symptoms. While dystonia may involve shaking, it typically results in rigidity rather than gradual onset and offset.

Understanding Psychogenic Non-Epileptic Seizures

Psychogenic non-epileptic seizures, also known as pseudoseizures, are a type of seizure that is not caused by abnormal electrical activity in the brain. Instead, they are believed to be caused by psychological factors such as stress, trauma, or anxiety. These seizures can be difficult to diagnose as they often mimic true epileptic seizures, but there are certain factors that can help differentiate between the two.

Factors that may indicate pseudoseizures include pelvic thrusting, a family history of epilepsy, a higher incidence in females, crying after the seizure, and the seizures not occurring when the individual is alone. On the other hand, factors that may indicate true epileptic seizures include tongue biting and a raised serum prolactin level.

Video telemetry is a useful tool for differentiating between the two types of seizures. It involves monitoring the individual’s brain activity and behavior during a seizure, which can help determine whether it is caused by abnormal electrical activity in the brain or psychological factors.

It is important to accurately diagnose and treat psychogenic non-epileptic seizures as they can have a significant impact on an individual’s quality of life. Treatment may involve therapy to address underlying psychological factors, as well as medication to manage any associated symptoms such as anxiety or depression.

Based on the information provided in the presentation and the patient’s medical history, it can be concluded that the patient is experiencing diabetic ketoacidosis (DKA), which results in metabolic acidosis and an elevated anion gap.

Arterial Blood Gas Interpretation Made Easy

Arterial blood gas interpretation can be a daunting task for healthcare professionals. However, the Resuscitation Council (UK) has provided a simple 5-step approach to make it easier. The first step is to assess the patient’s overall condition. The second step is to determine if the patient is hypoxaemic, which is indicated by a PaO2 level of less than 10 kPa on air. The third step is to check if the patient is academic or alkalaemic, which is determined by the pH level. A pH level of less than 7.35 indicates acidaemia, while a pH level of more than 7.45 indicates alkalaemia.

The fourth step is to assess the respiratory component by checking the PaCO2 level. A PaCO2 level of more than 6.0 kPa suggests respiratory acidosis, while a PaCO2 level of less than 4.7 kPa suggests respiratory alkalosis. The fifth and final step is to evaluate the metabolic component by checking the bicarbonate level or base excess. A bicarbonate level of less than 22 mmol/l or a base excess of less than -2mmol/l indicates metabolic acidosis, while a bicarbonate level of more than 26 mmol/l or a base excess of more than +2mmol/l indicates metabolic alkalosis.

To make it easier to remember, healthcare professionals can use the ROME acronym. Respiratory is opposite, which means that low pH and high PaCO2 indicate acidosis, while high pH and low PaCO2 indicate alkalosis. Metabolic is equal, which means that low pH and low bicarbonate indicate acidosis, while high pH and high bicarbonate indicate alkalosis. By following this simple approach, healthcare professionals can easily interpret arterial blood gas results and provide appropriate treatment for their patients.

Haemochromatosis is identified by an iron study profile that shows elevated levels of transferrin saturation and ferritin, along with a low total iron-binding capacity. This condition is inherited and leads to an excessive buildup of iron in the body. To rule out other possibilities, any options that do not show increased levels of ferritin and transferrin saturation can be eliminated during initial screening. Transferrin is a protein that transports iron in the blood, and its levels rise during iron deficiency to maximize the use of available iron. Total iron-binding capacity reflects the number of iron-binding sites on transferrin, and its levels increase during iron deficiency and decrease during iron overload.

Understanding Haemochromatosis: Investigation and Management

Haemochromatosis is a genetic disorder that causes iron accumulation in the body due to mutations in the HFE gene on both copies of chromosome 6. The best investigation to screen for haemochromatosis is still a topic of debate. For the general population, transferrin saturation is considered the most useful marker, while genetic testing for HFE mutation is recommended for testing family members. Diagnostic tests include molecular genetic testing for the C282Y and H63D mutations and liver biopsy with Perl’s stain. A typical iron study profile in a patient with haemochromatosis includes high transferrin saturation, raised ferritin and iron, and low TIBC.

The first-line treatment for haemochromatosis is venesection, which involves removing blood from the body to reduce iron levels. Transferrin saturation should be kept below 50%, and the serum ferritin concentration should be below 50 ug/l to monitor the adequacy of venesection. If venesection is not effective, desferrioxamine may be used as a second-line treatment. Joint x-rays may show chondrocalcinosis, which is a characteristic feature of haemochromatosis. It is important to note that there are rare cases of families with classic features of genetic haemochromatosis but no mutation in the HFE gene.

Sotalol is the only beta blocker known to cause long QT syndrome. Tricyclic antidepressants, selective serotonin reuptake inhibitors, and haloperidol can also cause QTc prolongation, while benzodiazepines and short-acting beta-receptor agonists are not known to have this effect.

Understanding Long QT Syndrome

Long QT syndrome (LQTS) is a genetic condition that causes delayed repolarization of the ventricles, which can lead to ventricular tachycardia and sudden death. The most common types of LQTS are caused by defects in the alpha subunit of the slow delayed rectifier potassium channel. A normal corrected QT interval is less than 430 ms in males and 450 ms in females.

There are various causes of a prolonged QT interval, including congenital factors, drugs, and other medical conditions. Some drugs that can prolong the QT interval include amiodarone, tricyclic antidepressants, and selective serotonin reuptake inhibitors. Electrolyte imbalances, acute myocardial infarction, and subarachnoid hemorrhage can also cause a prolonged QT interval.

LQTS may be picked up on routine ECG or following family screening. The symptoms and events associated with LQTS can vary depending on the type of LQTS. Long QT1 is usually associated with exertional syncope, while Long QT2 is often associated with syncope following emotional stress or exercise. Long QT3 events often occur at night or at rest.

Management of LQTS involves avoiding drugs that prolong the QT interval and other precipitants if appropriate. Beta-blockers may be used, and in high-risk cases, implantable cardioverter defibrillators may be necessary. It is important to recognize and manage LQTS to prevent sudden cardiac death.

The appropriate course of action for a patient with poorly controlled hypertension who is already taking an ACE inhibitor is to add indapamide to their medication regimen. This is in accordance with the NICE treatment algorithm, which recommends adding a calcium channel blocker or a thiazide-like diuretic in such cases. It is important to note that nifedipine should be avoided in patients with heart failure, and that amlodipine is the only calcium channel blocker licensed for use in such patients. Continuing to monitor blood pressure at home and reviewing in one month would not be sufficient in this case, as the patient’s hypertension needs to be addressed more aggressively. Stopping ramipril and trying amlodipine instead is not recommended, as combination therapy is the preferred approach. Similarly, stopping ramipril and trying amlodipine with indapamide instead is not recommended, as the combination should not be used in place of an ACE inhibitor.

NICE Guidelines for Managing Hypertension

Hypertension, or high blood pressure, is a common condition that can lead to serious health problems if left untreated. The National Institute for Health and Care Excellence (NICE) has published updated guidelines for the management of hypertension in 2019. Some of the key changes include lowering the threshold for treating stage 1 hypertension in patients under 80 years old, allowing the use of angiotensin receptor blockers instead of ACE inhibitors, and recommending the use of a calcium channel blocker or thiazide-like diuretic in addition to an ACE inhibitor or angiotensin receptor blocker.

The guidelines also provide a flow chart for the diagnosis and management of hypertension. Lifestyle advice, such as reducing salt intake, caffeine intake, and alcohol consumption, as well as exercising more and losing weight, should not be forgotten and is frequently tested in exams. Treatment options depend on the patient’s age, ethnicity, and other factors, and may involve a combination of drugs.

NICE recommends treating stage 1 hypertension in patients under 80 years old if they have target organ damage, established cardiovascular disease, renal disease, diabetes, or a 10-year cardiovascular risk equivalent to 10% or greater. For patients with stage 2 hypertension, drug treatment should be offered regardless of age. The guidelines also provide step-by-step treatment options, including adding a third or fourth drug if necessary.

New drugs, such as direct renin inhibitors like Aliskiren, may have a role in patients who are intolerant of more established antihypertensive drugs. However, trials have only investigated the fall in blood pressure and no mortality data is available yet. Patients who fail to respond to step 4 measures should be referred to a specialist. The guidelines also provide blood pressure targets for different age groups.

Criteria for Liver Transplant Recommendation at King’s College Hospital

The King’s College Hospital Liver Transplant Unit has specific criteria for recommending a liver transplant. These criteria include an arterial pH of less than 7.3 or arterial lactate levels greater than 3.0 mmol/L after fluid rehydration. Additionally, if a patient experiences all three of the following conditions within a 24-hour period, a liver transplant may be recommended: PT levels greater than 100 seconds, creatinine levels greater than 300 µmol/L, and Grade III/IV encephalopathy.

It is important to note that mild elevations in creatinine levels may occur due to dehydration, and rises in transaminases may be seen as a result of hepatocellular damage. Therefore, these factors are not necessarily indicative of the need for a liver transplant. The specific criteria outlined by the King’s College Hospital Liver Transplant Unit are used to ensure that patients who truly require a liver transplant receive one in a timely manner.

When clopidogrel cannot be used, the recommended treatment for secondary stroke prevention is a combination of aspirin 75 mg and modified-release dipyridamole. Studies have shown that this combination is more effective than taking either medication alone. Ticagrelor is not currently recommended for this purpose by NICE, and prasugrel is contraindicated due to the risk of bleeding. Oral anticoagulants like warfarin are generally not used for secondary stroke prevention, with antiplatelets being the preferred treatment.

The Royal College of Physicians (RCP) and NICE have published guidelines on the diagnosis and management of patients following a stroke. The management of acute stroke includes maintaining normal levels of blood glucose, hydration, oxygen saturation, and temperature. Blood pressure should not be lowered in the acute phase unless there are complications. Aspirin should be given as soon as possible if a haemorrhagic stroke has been excluded. Anticoagulants should not be started until brain imaging has excluded haemorrhage. Thrombolysis with alteplase should only be given if administered within 4.5 hours of onset of stroke symptoms and haemorrhage has been definitively excluded. Mechanical thrombectomy is a new treatment option for patients with an acute ischaemic stroke. NICE recommends thrombectomy for people who have acute ischaemic stroke and confirmed occlusion of the proximal anterior circulation demonstrated by computed tomographic angiography or magnetic resonance angiography. Secondary prevention includes the use of clopidogrel and dipyridamole. Carotid artery endarterectomy should only be considered if carotid stenosis is greater than 70% according to ECST criteria or greater than 50% according to NASCET criteria.

Sjögren’s Syndrome and its Ocular Manifestations

Sjögren’s syndrome is an autoimmune disease that primarily affects the exocrine glands, leading to decreased production of tears and saliva. This results in dry eyes and dry mouth, which can cause corneal abrasions and even ulceration if left untreated. It is commonly associated with connective tissue diseases, particularly rheumatoid arthritis.

When it comes to ocular manifestations, it is important to differentiate Sjögren’s syndrome from other conditions such as scleritis, episcleritis, uveitis, and ulcerative keratitis. The phenylephrine test can help distinguish between episcleritis and scleritis, while uveitis typically presents with ocular pain, photophobia, and blurred vision. Ulcerative keratitis, on the other hand, has an infectious presentation and requires different treatment approaches depending on the depth of the ulcer.

Overall, the pathophysiology and ocular manifestations of Sjögren’s syndrome is crucial for proper diagnosis and management of this autoimmune disease.

For patients under 65 years old with subclinical hypothyroidism and a TSH level between 5.5-10mU/L, a 6-month trial of thyroxine should be offered if they have hypothyroidism symptoms and their TSH remains elevated on two separate occasions 3 months apart. This is because subclinical hypothyroidism increases the risk of cardiovascular disease and progression to overt hypothyroidism, and treatment with levothyroxine generally resolves symptoms. Repeat thyroid autoantibody tests and thyroid function testing after 3 months are unnecessary if the patient has already had negative autoantibody results and two elevated TSH levels 3 months apart. Prescribing levothyroxine only if further symptoms develop is not recommended as it delays treatment and increases the risk of negative impacts on the patient’s quality of life.

Understanding Subclinical Hypothyroidism

Subclinical hypothyroidism is a condition where the thyroid-stimulating hormone (TSH) is elevated, but the levels of T3 and T4 are normal, and there are no obvious symptoms. However, there is a risk of the condition progressing to overt hypothyroidism, especially in men, with a 2-5% chance per year. This risk is further increased if thyroid autoantibodies are present.

Not all patients with subclinical hypothyroidism require treatment, and guidelines have been produced by NICE Clinical Knowledge Summaries (CKS) to help determine when treatment is necessary. If the TSH level is above 10mU/L and the free thyroxine level is within the normal range, levothyroxine may be offered. If the TSH level is between 5.5 – 10mU/L and the free thyroxine level is within the normal range, a 6-month trial of levothyroxine may be considered if the patient is under 65 years old and experiencing symptoms of hypothyroidism. For older patients, a ‘watch and wait’ strategy is often used, and asymptomatic patients may simply have their thyroid function monitored every 6 months.

In summary, subclinical hypothyroidism is a condition that requires careful monitoring and consideration of treatment options based on individual patient factors.

Macrolides have the potential to cause torsades de pointes, a type of polymorphic ventricular tachycardia that is linked to a prolonged QT interval. Symptoms of torsades de pointes may include chest pain, hypotension, palpitations, shortness of breath, syncope, and tachycardia. Erythromycin is the correct answer as it is a macrolide that can lead to a prolonged QT interval and increase the risk of torsades de pointes. Other potential side effects of erythromycin include acute cholestatic hepatitis, eosinophilia, and gastrointestinal upset. Gentamicin, on the other hand, is an aminoglycoside that is not associated with torsades de pointes but can cause ototoxicity and nephrotoxicity. Promethazine is a first-generation antihistamine that can cause sedation and anticholinergic effects, but it is not linked to torsades de pointes. Similarly, salbutamol, a beta-2-agonist, can cause headaches, palpitations, and tremors, but it is not associated with torsades de pointes.

Torsades de Pointes: A Life-Threatening Condition

Torsades de pointes is a type of ventricular tachycardia that is associated with a prolonged QT interval. This condition can lead to ventricular fibrillation, which can cause sudden death. There are several causes of a prolonged QT interval, including congenital conditions such as Jervell-Lange-Nielsen syndrome and Romano-Ward syndrome, as well as certain medications like antiarrhythmics, tricyclic antidepressants, and antipsychotics. Other causes include electrolyte imbalances, myocarditis, hypothermia, and subarachnoid hemorrhage.

The management of torsades de pointes involves the administration of intravenous magnesium sulfate. This can help to stabilize the heart rhythm and prevent further complications.